Cabozantinib for treating medullary thyroid cancer
Technology appraisal guidance
Reference number: TA516
Published:
Ipsen requested to submit an updated value proposition for cabozantinib, which has been accepted. This will be discussed at the technology appraisal committee on 9 January 2018 in a closed, private session.